Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

IDXG•2026-08-10

Margins and test volume

Gross margin expanded to 62% from 54% on a pro forma thyroid-only basis; thyroid test volume rose 6% year over year.

Q2 results and profitability

Interpace Biosciences posted Q2 revenue of $9.1 million, down 1% year over year, on a 9% rise in thyroid revenue.

Income from continuing operations turned to profit at $0.3 million, including about $200,000 of non-recurring professional fees.

Non-GAAP adjusted EBITDA climbed to $0.7 million, lifting margin to 8%.

Operational updates and product development

Thyroid lab automation moved into production; pancreatic cancer test development advanced with analytical validation underway and no expected 2026 revenue contribution.

Sources

Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

Publicnow

Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

Margins and test volume

Q2 results and profitability

Operational updates and product development

Related News

Lululemon's Chief Strategy Officer Acheson Exits Month Before CEO Joins Troubled Chain

Ur-Energy starts full production operations at Shirley Basin uranium project after Wyoming approval

Kyndryl Announces Agreement To Purchase Healthcare IT Leaders

Sources

Interpace Biosciences Q2 FY26 swings to GAAP profit of $266,000; revenue falls 1% to $9.1 million

Oramed swings to Q2 FY26 net income of $78.16 million; operating loss widens 11% to $2.77 million

UPS Issues $1.00B Of 4.850% Senior Notes Due 2031